Company: CRNX
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057452
Chunk: 39

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 39
---
isable as of April 14, 2025 or that will become exercisable within 60 days after such date.

Includes 109,246 shares of common stock and 90,000 shares of common stock underlying options held by Dr. Wierenga that are exercisable as of April 14, 2025 or that will become exercisable within 60 days after such date.

Includes 9,400 shares of common stock and 72,775 shares of common stock underlying options held by Ms. Deardorf that are exercisable as of April 14, 2025 or that will become exercisable within 60 days after such date.

Includes 14,400 shares of common stock and 77,150 shares of common stock underlying options held by Dr. Vivaldi that are exercisable as of April 14, 2025 or that will become exercisable within 60 days after such date.

Consists of 1,753,716 shares of common stock and 2,626,366 shares of common stock issuable upon exercise of outstanding options which are exercisable as of April 14, 2025 or that will become exercisable within 60 days after such date, as set forth in previous footnotes.

Delinquent Section 16(a) Reports

Section 16(a) of the Exchange Act requires our Directors, executive officers, and persons who own more than ten percent of a registered class of our equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock and other equity securities. Such persons are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file.

To our knowledge, based on a review of Section 16 reports submitted on EDGAR and written representations from the reporting persons that, during the fiscal year ended December 31, 2024, our officers, Directors and greater than ten percent beneficial owners complied with all applicable Section 16(a) filing requirements, except for one Form 3, as a result of obtaining EDGAR filing codes after the due date of the initial Form 3, was filed late by Ms. Kalofonos on December 16, 2024.

<div align='center'>25</div>

EXECUTIVE OFFICERS Our Executive Officers The following table sets forth the name, age and position of each of our executive officers as of April 14, 2025.

| Name                      |     | Age |     | Position                                        |
| R